Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubitinib versus chemotherapy for PTPRZ1-MET fusion-positive recurrent secondary glioblastoma
CTR20181664Phase 2Active
- Sponsor
- Beijing Purunao Biotechnology
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib in glioblastoma (GBM), secondary glioblastoma (sGBM), glioma, sponsored by Beijing Purunao Biotechnology. Started Dec 2018; status: active.
02
Drugs
vebreltinib
03
Conditions
glioblastoma (GBM)secondary glioblastoma (sGBM)glioma
Beyond the preview
Go deeper on CTR20181664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181664.